×
GreekEnglish

×
  • Politics
  • Diaspora
  • World
  • Lifestyle
  • Travel
  • Culture
  • Sports
  • Cooking
Saturday
21
Nov 2026
weather symbol
Athens 18°C
  • Home
  • Politics
  • Economy
  • World
  • Diaspora
  • Lifestyle
  • Travel
  • Culture
  • Sports
  • Mediterranean Cooking
  • Weather
Contact follow Protothema:
Powered by
> World

Lung cancer: New pill produces unprecedented results in human trial

Results revealed that 60% of patients on lorlatinib were alive without disease progression five years after treatment

Newsroom June 5 12:48

Δείτε περισσότερα άρθρα μας στα αποτελέσματα αναζήτησης

Add Protothema.gr on Google

Lung cancer is the leading cause of cancer-related deaths globally. A trial for a new anti-cancer drug showed that five years post-treatment, 60% of patients with a common form of lung cancer were still alive, with their cancer not progressing. This trial targeted the ALK protein, which is produced by the ALK gene. In non-small cell lung cancer (NSCLC), this gene can be rearranged, leading to aggressive cancer growth. ALK-positive tumors occur in about 3% to 5% of NSCLC cases, usually affecting younger, light, or non-smokers.

Lorlatinib, a third-generation ALK inhibitor, was tested in an international clinical trial led by Peter MacCallum Cancer Center in Melbourne, Australia. The study focused on patients with advanced ALK-positive NSCLC. In this Phase III trial, 296 patients were randomly assigned to receive either lorlatinib or crizotinib, a first-generation ALK inhibitor. The primary endpoint was progression-free survival, with secondary endpoints including overall survival and brain metastasis.

Results revealed that 60% of patients on lorlatinib were alive without disease progression five years after treatment, compared to 8% on crizotinib. Lorlatinib showed an 81% reduction in cancer progression or death and a 94% reduction in brain metastasis progression compared to crizotinib. The updated analysis confirmed that lorlatinib helps patients live longer without disease progression, with many patients experiencing sustained benefits for over five years.

>Related articles

Ninth informal vote for UN Secretary-General ends in deadlock, with Grynspan again in the lead

“72-hour survival kits” in Europe, “Fortress America” plan in the US: Pentagon prepares for 90 days without electricity or resupply amid fears of a total blackout

Trump’s interview following the China trilateral meeting: I want the war in Ukraine to end immediately, but the problem is the hatred between Putin & Zelensky (video)

See Also:

Ellinikon: Over 30 cranes at the project – How the houses and infrastructure projects are progressing (photos)

Despite higher adverse event rates with lorlatinib compared to crizotinib (77% versus 57%), these events were manageable with dose adjustments and did not affect the drug’s efficacy. The study, presenting the longest progression-free survival data for any single-agent targeted treatment in advanced NSCLC, marks significant progress in lung cancer treatment. The trial results were highlighted at the 2024 American Society of Clinical Oncology (ASCO) meeting and published in the Journal of Clinical Oncology.

Ask me anything

Explore related questions

#health#lung cancer#medicine#pill#science#technology#treatment#world
> More World

Follow en.protothema.gr on Google News and be the first to know all the news

See all the latest News from Greece and the World, the moment they happen, at en.protothema.gr

> Latest Stories

Macron: Russia is escalating its aggression in Europe and playing a reckless game

November 21, 2026

Boat carrying 47 migrants spotted south of Crete, rescued by tanker

November 21, 2026

Ninth informal vote for UN Secretary-General ends in deadlock, with Grynspan again in the lead

November 20, 2026

“72-hour survival kits” in Europe, “Fortress America” plan in the US: Pentagon prepares for 90 days without electricity or resupply amid fears of a total blackout

November 20, 2026

Trump’s interview following the China trilateral meeting: I want the war in Ukraine to end immediately, but the problem is the hatred between Putin & Zelensky (video)

November 20, 2026

Eisenkot to attempt to form a government in Israel even without a majority, as Netanyahu issues warning

November 20, 2026

Sting to perform in Greece next summer in highly anticipated concert

November 20, 2026

Lagarde: Europe must anticipate crises, not play catch-up – A warning over the economy

November 20, 2026
All News

> Greece

In reverence, the emotional deposition in Jerusalem, see photos & video

The Holy Temple of the Resurrection opened after many days due to the war between Israel and Iran

April 10, 2026

In the final stretch for the accreditation of joint master’s degrees: Aiming for their launch in the coming academic year

April 10, 2026

Schedule for Epitaph Procession today (10/4)

April 10, 2026

Perfect weather for Easter excursions, according to Tsatrafyllia’s forecast

April 10, 2026

Easter in Greece: The customs that continue in Greek tradition – From Nafpaktos to Corfu

April 10, 2026
Homepage
PERSONAL DATA PROTECTION POLICY COOKIES POLICY TERM OF USE
Powered by Cloudevo
Copyright © 2026 Πρώτο Θέμα